# OnCo record paper-dreamseq-jco-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-dreamseq-jco-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-dreamseq-jco-2023" ;
  schema:name "DREAMseq (ECOG-ACRIN EA6134): sequencing dabrafenib-trametinib and nivolumab-ipilimumab in BRAF-mutant metastatic melanoma"@en ;
  schema:description "Starting with nivolumab plus ipilimumab and switching to BRAF-MEK inhibitors at progression gave 20 percentage points better two-year survival than the reverse order in BRAF-mutant advanced melanoma, settling the question of which to use first."@en ;
  schema:url <https://onco.cc/key-papers/paper-dreamseq-jco-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.22.01763>, <https://pubmed.ncbi.nlm.nih.gov/36166727/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.22.01763> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Atkins MB, Lee SJ, Chmielowski B, et al." ;
  onco:cancers <https://onco.cc/cancers/advanced-melanoma/>, <https://onco.cc/cancers/braf-v600-melanoma/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/trametinib/> ;
  onco:trials <https://onco.cc/trials/dreamseq/> ;
  onco:journals <https://onco.cc/journals/jco/> .